STOPDAPT-2 ACS Mortality Prediction Tool
This page collects selected clinical characteristics for review. The supplied source code used placeholder regression coefficients, and a validated equation for individual 12-month mortality prediction was not provided. For patient safety, this version does not generate a patient-specific mortality percentage.
Clinical profile
Enter the available patient characteristics. All fields are required for profile validation.
Clinical context
STOPDAPT-2 ACS was a randomized clinical trial comparing 1–2 months of dual antiplatelet therapy followed by clopidogrel monotherapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome undergoing PCI. It evaluated antithrombotic treatment strategies and clinical outcomes; it should not be treated as a validated individual mortality calculator.
What the source trial reported
The trial's primary endpoint was a composite of cardiovascular outcomes and TIMI major or minor bleeding. The abbreviated DAPT strategy did not meet the prespecified criterion for noninferiority for that composite endpoint. The trial also reported all-cause death as a clinical outcome, but those group-level event rates are not a patient-specific prediction equation.
Variables in this profile
- Age and serum creatinine.
- Left ventricular ejection fraction.
- Killip class.
- ST-segment deviation on ECG.
The presence of these variables in this form does not mean that they constitute a validated STOPDAPT-2 ACS mortality model.
Reference
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.